Head-To-Head Survey: Edesa Biotech (NASDAQ:EDSA) and Earth Science Tech (OTCMKTS:ETST)

Earth Science Tech (OTCMKTS:ETST) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Risk and Volatility

Earth Science Tech has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Institutional & Insider Ownership

5.5% of Edesa Biotech shares are owned by institutional investors. 24.9% of Earth Science Tech shares are owned by insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Earth Science Tech and Edesa Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Earth Science Tech	0	0	0	0	0.00
Edesa Biotech	0	0	1	0	3.00

Edesa Biotech has a consensus price target of $21.00, suggesting a potential upside of 809.09%. Given Edesa Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Earth Science Tech.

Profitability

This table compares Earth Science Tech and Edesa Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Earth Science Tech	N/A	N/A	N/A
Edesa Biotech	N/A	-233.69%	-124.14%

Valuation & Earnings

This table compares Earth Science Tech and Edesa Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Earth Science Tech	$11.95 million	3.39	$810,000.00	N/A	N/A
Edesa Biotech	N/A	N/A	-$6.17 million	($1.87)	-1.24

Earth Science Tech has higher revenue and earnings than Edesa Biotech.

About Earth Science Tech

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

About Edesa Biotech

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.